Bioventus Aims for $100M+ in PNS Revenue with New Product Clearances

Bioventus Inc. reported Q2 2025 revenue of $148 million, with organic growth of 6%, driven by the strength of its diverse portfolio. CEO Robert E. Claypoole outlined a path to $100M+ PNS revenue opportunity, with new products receiving clearance.

Bioventus Inc. (Nasdaq: BVS) reported its second-quarter 2025 financial results, with revenue of $147.7 million, a decline of 2.4% from the prior-year period. Despite this, the company's organic revenue advanced by 6.2%, driven by strong performance across its Surgical Solutions and Restorative Therapies segments [1].

The company's net income attributable to Bioventus Inc. improved significantly, rising to $7.5 million from a net loss of $25.7 million in the prior-year period. Adjusted EBITDA was $33.8 million, down from $34.5 million due to the impact of the divestiture of the Advanced Rehabilitation Business and foreign currency fluctuations [1].

CEO Rob Claypoole highlighted the company's strategic priorities, including the recent FDA clearances for TalisMann and StimTrial, which create new growth opportunities for the company. These products are expected to contribute to a significant revenue expansion in the Peripheral Nerve Stimulation (PNS) market, with a total addressable market of approximately $2 billion in the U.S. [1].

The company's financial guidance for the full year 2025 remains unchanged, with net sales expected to be between $560 million and $570 million, Adjusted EBITDA of $112 million to $116 million, and Non-GAAP EPS of $0.64 to $0.68 [1].

Bioventus also announced a new credit agreement on July 31, 2025, for a $300 million term loan and a $100 million revolving credit facility, which provides over $2 million in annual interest expense savings and increased liquidity [1].

References:
[1] https://www.biospace.com/press-releases/bioventus-reports-second-quarter-2025-financial-results